| Alopecia Areata
Olumiant vs Litfulo
Side-by-side clinical, coverage, and cost comparison for alopecia areata.Deep comparison between: Olumiant vs Litfulo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLitfulo has a higher rate of injection site reactions vs Olumiant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Litfulo but not Olumiant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Olumiant
Litfulo
At A Glance
Oral
Once daily
JAK inhibitor
Oral
Daily
JAK3/TEC kinase inhibitor
Indications
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
- Alopecia Areata
Dosing
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
Alopecia Areata 50 mg orally once daily with or without food; swallow capsules whole, do not crush, split, or chew.
Contraindications
—
- Known hypersensitivity to ritlecitinib or any of its excipients
Adverse Reactions
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Most common (>=1%) Headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, blood creatine phosphokinase increased, herpes zoster, red blood cell count decreased, stomatitis
Serious Serious infections (appendicitis, COVID-19 pneumonia, sepsis), malignancy, thromboembolic events (pulmonary embolism, retinal artery occlusion, acute myocardial infarction)
Pharmacology
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
Ritlecitinib irreversibly inhibits JAK3 and the TEC kinase family by blocking the ATP binding site, suppressing cytokine-induced STAT phosphorylation via JAK3-dependent receptors and inhibiting signaling of immune receptors dependent on TEC kinase family members.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Litfulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Litfulo
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Litfulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Pfizer Dermatology Patient Access Interim Care Rx Program: LitfuloCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OlumiantView full Olumiant profile
LitfuloView full Litfulo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.